Who We Are - Founders
Sydney Brenner and Philip Goelet have known each other since 1979, when Philip came to work with Dr. Jonathan Karn, a colleague of Sydney’s at the Laboratory of Molecular Biology, Cambridge University, UK. Before founding Acidophil, Sydney co-founded Combichem and Lynx Therapeutics, and Philip co-founded Molecular Tool and Ribotargets. Since founding Acidophil, Sydney and Philip have co-founded Population Genetics Technologies with Sam Eletr, in addition to Arginetix, ZuvaChem, and AgriMetis.
Sydney Brenner MD PhD (Board Member and Scientific Advisor) is a Fellow of the Royal Society, a Foreign Associate of the National Academy of Sciences, a recipient of the Albert Lasker Medical Research Award, 1971, and was awarded the Nobel Prize in Medicine in 2002 for his pioneering work in genetics and molecular biology. He participated in the discovery of messenger RNA and, with Francis Crick, showed that the genetic code was composed of triplets. He is the principal investigator of the massively parallel DNA analysis technologies of Lynx Therapeutics and was a member of the board of directors from 1993 to 2001. He began his career in the Cavendish Laboratory in Cambridge, and became the Director of its successor, the MRC Laboratory of Molecular Biology, in 1979. He became the Director of the MRC Unit of Molecular Genetics in 1987, retiring in 1992. He is a founder of Combichem, Inc. and served on its Scientific Advisory Board. He founded the Molecular Sciences Institute in Berkley and retired as Director of Research in February 2001. He is now a Distinguished Research Professor of The Salk Institute, La Jolla, California.
Philip Goelet PhD (Board Member and Chief Executive Officer) is a scientist, entrepreneur and investor. After his PhD in Molecular Biology at Cambridge University, UK he worked as a post doctoral student with Dr. Eric Kandel at Columbia University on learning and memory. Since 1990, he has co-founded and invested in a number of biotechnology companies including Molecular Tool, Inc., RiboTargets, Plc., Dihedron, Inc., Population Genetic Technologies, Ltd, Arginetix, Inc., ZuvaChem, LLC and AgriMetis, LLC. Between 1995 and 2001, he served as a director of the Rhode Island Corporation, a private investment company, and its successor, NORIC, which was acquired by Pogo Producing Company. In 2003, he co-founded Red Abbey Venture Partners, a life sciences private equity fund, with Frank Bonsal and Matt Zuga. His principal focus today is Acidophil and its affiliated companies.